Wells Fargo lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $20 from $42 and keeps an Overweight rating on the shares. The firm Phase 2 data suggests establishing efficacy of inhaled mRNA may take more effort than expected. Wells does think mucus reduction data are intriguing, especially with anatomical consistency.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Why Is Arcturus Therapeutics Stock (ARCT) Down 55% Today?
- Optimistic Buy Rating for Arcturus Therapeutics Amid Promising mRNA Therapy Developments
- Arcturus Therapeutics downgraded to Neutral from Buy at Guggenheim
- Arcturus Therapeutics Announces Phase 2 Trial Results